Neurotrope Inc (NASDAQ:NTRP) was the target of a large growth in short interest in the month of June. As of June 30th, there was short interest totalling 293,800 shares, a growth of 13.7% from the May 30th total of 258,300 shares. Based on an average daily volume of 64,900 shares, the days-to-cover ratio is presently 4.5 days. Currently, 5.9% of the company’s shares are short sold.
An institutional investor recently bought a new position in Neurotrope stock. MYDA Advisors LLC acquired a new position in shares of Neurotrope Inc (NASDAQ:NTRP) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 126,685 shares of the company’s stock, valued at approximately $690,000. MYDA Advisors LLC owned 0.98% of Neurotrope as of its most recent SEC filing. Institutional investors and hedge funds own 13.85% of the company’s stock.
A number of analysts have weighed in on the stock. Janney Montgomery Scott assumed coverage on shares of Neurotrope in a research report on Tuesday, June 18th. They set a “buy” rating and a $14.00 target price for the company. ValuEngine raised shares of Universal Logistics from a “strong sell” rating to a “sell” rating in a research report on Thursday, March 28th.
NASDAQ:NTRP opened at $6.57 on Tuesday. The firm has a market cap of $84.68 million, a P/E ratio of -4.80 and a beta of 2.46. The firm’s 50 day moving average price is $7.21. Neurotrope has a fifty-two week low of $3.33 and a fifty-two week high of $11.90.
Neurotrope (NASDAQ:NTRP) last released its earnings results on Thursday, May 9th. The company reported ($0.36) earnings per share for the quarter. On average, analysts forecast that Neurotrope will post -1.56 earnings per share for the current fiscal year.
Neurotrope Company Profile
Neurotrope, Inc, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease. Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X syndrome, multiple sclerosis, and niemann-pick type C diseases.
Featured Article: Commodities
Receive News & Ratings for Neurotrope Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurotrope and related companies with MarketBeat.com's FREE daily email newsletter.